Pirard Delphine, Heenen Michel, Melot Christian, Vereecken Pierre
Department of Dermatology, Erasme Hospital, Brussels, Belgium.
Dermatology. 2004;208(1):43-8. doi: 10.1159/000075045.
The literature on the benefit of alpha-interferon (IFN-alpha) as adjuvant postsurgical treatment of melanoma reports discordant results.
With the published data so far, we performed a meta-analysis in order to evaluate the effect of IFN-alpha on the relapse rate (RR) and the overall survival (OS).
Published randomised trials were identified by Medline search. Stage IV melanoma was not considered.
Nine published studies were included, with a total of 2,880 patients. Both the per protocol and the intention-to-treat analysis show that IFN-alpha significantly decreased the RR (OR = 0.74; 95% CI = 0.64-0.86). Subgroup analyses show that, for all stages, high and low doses decreased the RR (OR = 0.71, 95% CI = 0.54-0.92, and OR = 0.76, 95% CI = 0.63-0.91, respectively). No difference has been evidenced on OS.
High and low doses of IFN-alpha significantly decrease the RR, but the OS does not seem to be improved.
关于α-干扰素（IFN-α）作为黑色素瘤术后辅助治疗的益处的文献报道结果不一致。
基于目前已发表的数据，我们进行了一项荟萃分析，以评估IFN-α对复发率（RR）和总生存期（OS）的影响。
通过检索Medline确定已发表的随机试验。未考虑IV期黑色素瘤。
纳入9项已发表的研究，共2880例患者。符合方案分析和意向性分析均显示，IFN-α显著降低了RR（OR = 0.74；95%CI = 0.64 - 0.86）。亚组分析表明，对于所有分期，高剂量和低剂量均降低了RR（OR分别为0.71，95%CI = 0.54 - 0.92和OR = 0.76，95%CI = 0.63 - 0.91）。在OS方面未发现差异。
高剂量和低剂量的IFN-α均显著降低RR，但OS似乎未得到改善。
